MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2022 International Congress

    Alteration of lysosomal enzymatic activities in blood of patients with schizophrenia

    A. Bezrukova, K. Basharova, M. Nikolaev, E. Palchikova, I. Miliukhina, G. Baydakova, N. Zalutskaya, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To estimate whether alteration of lysosomal activities contributes to schizophrenia (SCZ) pathogenesis, age at onset and risk of developing the disease. Background: SCZ is…
  • 2022 International Congress

    Antipsychotic use in Parkinson’s disease: a single center retrospective chart review

    S. Brooker, C. Yeh, D. Larson (Chicago, USA)

    Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…
  • 2022 International Congress

    Longitudinal study of clinical symptoms associated with psychosis in Parkinson’s disease without dementia

    J. Flanigan, M. Harrison, B. Shah, J. Patrie, K. Wyman-Chick, W. Dalrymple, S. Sperling, M. Barrett (Charlottesville, USA)

    Objective: Examine clinical features associated with psychosis among Parkinson’s disease (PD) patients without dementia. Background: Previously identified risk factors for PD psychosis include duration and…
  • 2022 International Congress

    A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…
  • 2022 International Congress

    Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine whether the therapeutic effect of serotonin 2A (5-HT2A) receptor antagonism on dyskinesia and psychosis may be reversed by orthosteric antagonism of metabotropic…
  • 2022 International Congress

    Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study

    O. Koniashvili, G. Khachiashvili, L. Gabunia (Tbilisi, Georgia)

    Objective: We aimed to assess the average duration of Parkinson's disease at the time patient was diagnosed with specific neuropsychiatric disturbance, to study their prevalence…
  • 2022 International Congress

    Non-Invasive Brain Stimulation for the Treatment of Psychiatric Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis

    Y. Qu (Wuhan, China)

    Objective: This meta-analysis aims to assess the effect of NIBS technique for psychiatric symptoms in patients with PD. Background: Non-invasive brain stimulations (NIBS), especially repetitive…
  • 2022 International Congress

    ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries

    S. Kumar, N. Rashid, D. Doshi, K. Rajagopalan (Dover, USA)

    Objective: To examine health resource utilization (HRU) outcomes among PDP patients treated with PIMA vs. other AAPs. Background: Real-world analysis demonstrating pimavanserin (PIMA) benefits, the…
  • 2022 International Congress

    Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management

    O. Kaczmarek, S. Baek, A. Sethi, A. Stolarczyk, B. Bumstead, M. Buhse, M. Zarif, B. Anand, M. Gudesblatt (Patchogue, USA)

    Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…
  • 2022 International Congress

    Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease

    J. Potheegadoo, F. Bernasconi, O. Blanke (Geneva, Switzerland)

    Objective: Measuring experimentally-induced presence hallucinations in patients with Parkinson’s disease phantom boarder phenomena. Background: Phantom boarder syndrome (PB) is described as the sensation that someone…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley